

### Patient + Insurance Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  Male  Female SSN: \_\_\_\_\_ Wt (kg/lbs): \_\_\_\_\_ Ht (cm/in): \_\_\_\_\_  
 Address: \_\_\_\_\_ Phone: \_\_\_\_\_ Alternate: \_\_\_\_\_  
 Caregiver Name: \_\_\_\_\_ Relation to Patient: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Insurance Plan: \_\_\_\_\_ Plan ID: \_\_\_\_\_ BIN #: \_\_\_\_\_ PCN #: \_\_\_\_\_ GRP #: \_\_\_\_\_

Please fax a copy of the front and back of the insurance card(s).

### Prescriber + Shipping Information

Prescriber Name: \_\_\_\_\_ DEA: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Alternate: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_  
 If shipping to prescriber:  First Fill  Always  Never

### Clinical Information (Please fax all pertinent clinical and lab information)

#### Diagnosis Code:

Date of Diagnosis: \_\_\_\_\_  D67 (Type B – Factor IX Deficiency)  D68.2 (Hereditary deficiency of other clotting factors)  D68.0 (Von Willebrand Disease – Check Type:  1  2  3)  
 D66 (Type A – Factor VIII Deficiency)  D68.1 (Type C – Factor XI Deficiency)  D68.32 (Hemorrhagic disorder due to extrinsic circulating anticoagulants) \_\_\_\_\_  
 Circulating Factor \_\_\_\_\_% Target Joints:  No  Yes \_\_\_\_\_ Access:  Peripheral Butterfly  PICC  Implant Port  Broviac® / Hickman®  
 Severity:  Severe (<1%)  Moderate (1 - 5%)  Mild (>5%) Protocol:  Pre-Surgical  Prophylaxis  Immune Tolerance  On-demand  
 Inhibitor Activity:  None  Historical  Current \_\_\_\_\_ BU/mL Start Date: \_\_\_\_\_ End Date: \_\_\_\_\_  
 Comorbidities: \_\_\_\_\_  
 Concomitant Medications: \_\_\_\_\_  
 Allergies:  NKDA  Other: \_\_\_\_\_

### Prescription

Factor VIIa (Recombinant)	<input type="checkbox"/> NovoSeven® RT		
Factor VIII (Recombinant)	<input type="checkbox"/> Advate®	<input type="checkbox"/> Afstyla®	<input type="checkbox"/> Helixate® FS
	<input type="checkbox"/> Adynovate®	<input type="checkbox"/> Elocate™	<input type="checkbox"/> Kogenate® FS
Factor VIII (Human)	<input type="checkbox"/> Hemofil® M	<input type="checkbox"/> Monclate-P®	<input type="checkbox"/> NovoEight®
Factor VIII (Human) + VWF	<input type="checkbox"/> Alphanate® SD	<input type="checkbox"/> Humate-P®	<input type="checkbox"/> Koate® DVI
Factor IX (Recombinant)	<input type="checkbox"/> Alprolix®	<input type="checkbox"/> Benefix® RT	<input type="checkbox"/> Idelvion®
Factor IX (Human)	<input type="checkbox"/> AlphaNine® SD	<input type="checkbox"/> Mononine®	<input type="checkbox"/> Ixinity®
Factor X (Human)	<input type="checkbox"/> Coagadex®		<input type="checkbox"/> Rebinyn®
Factor XIII (Human)	<input type="checkbox"/> Corifact®		<input type="checkbox"/> Rixubis®
Anti-Inhibitor (Human)	<input type="checkbox"/> Feiba®		
Anti-Thrombin III (Human)	<input type="checkbox"/> Thrombate III®		
Protein C Concentrate (Recombinant)	<input type="checkbox"/> Ceprotein®		
Pro-Thrombin Complex (Human)	<input type="checkbox"/> Bebulin® VH	<input type="checkbox"/> Profilnine® SD	
Von Willebrand Factor (Recombinant)	<input type="checkbox"/> Vonvendi®		
Hemlibra®	<input type="checkbox"/> 30mg/ml	<input type="checkbox"/> 60mg/0.4ml	<input type="checkbox"/> Initial dose: 3mg/kg SQ once weekly for 4 weeks
	<input type="checkbox"/> 105mg/0.7ml	<input type="checkbox"/> 150mg/1ml	<input type="checkbox"/> Maintenance dose: 1.5mg/kg SQ once weekly Wt: _____ kg
Therapy Regimen for Factor or Inhibitor Products	<input type="checkbox"/> Prophylaxis _____/week		<input type="checkbox"/> Breakthrough bleed
	<input type="checkbox"/> Target Dose: _____ IU/kg		<input type="checkbox"/> Minor: _____ ± _____%
	<input type="checkbox"/> Dose: _____ IU ± _____% (Assay variation)		<input type="checkbox"/> Moderate: _____ ± _____%
	# Doses: _____ Refills: _____		<input type="checkbox"/> Major: _____ ± _____%
	<input type="checkbox"/> Immune Tolerance		<input type="checkbox"/> Target Dose: _____ IU/kg
			<input type="checkbox"/> Dose: _____ IU ± _____% (Assay variation)
	# Doses: _____ Refills: _____		# Doses: _____ Refills: _____

**Flushing Protocol**  Sodium Chloride 0.9% 5-10 mL pre and post medications  Heparin \_\_\_\_\_ units/mL \_\_\_\_\_ mL as needed

**Ancillary Supplies**  As needed for proper administration and disposal of medication

**Skilled Nursing Visits**  As needed for IV access, administration and proper clinical monitoring

All nursing services requirements to be completed per pharmacy protocol.

Other Medications	<input type="checkbox"/> Amicar®	<input type="checkbox"/> Tablet <input type="checkbox"/> Syrup	Directions: _____	Qty: _____	Refills: _____
	<input type="checkbox"/> Lysteda®		Directions: _____	Qty: _____	Refills: _____
	<input type="checkbox"/> Stimate®	<input type="checkbox"/> 150mcg <input type="checkbox"/> Wt < 50kg	Single spray in one nostril	Qty: _____	Refills: _____
		<input type="checkbox"/> 300mcg <input type="checkbox"/> Wt > 50kg	Single spray in both nostrils	Qty: _____	Refills: _____
	<input type="checkbox"/> _____		Directions: _____	Qty: _____	Refills: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: \_\_\_\_\_

Prescriber's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I authorize AmeriPharma and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to AmeriPharma.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 877-778-0318 to obtain instructions as to the proper destruction of the transmitted material. Thank you.